A Phase 3 interventional study of S-amlodipine gentisate and Amlodipine besylate in Hypertension, sponsored by SK Chemicals Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2007-03-06.
Sponsored by SK Chemicals Co., Ltd. · Phase 3, Interventional, and Treatment
The goal of this study is to compare the antihypertensive effect and tolerability of S-amlodipine gentisate with those of amlodipine besylate in patients with mild to moderate hypertension.
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's enrollment of 110 is above the median of 90 across 4,995 interventional studies indexed under Hypertension.
Browse Hypertension studies →SK Chemicals Co., Ltd. is the lead sponsor of 53 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The difference in mean changes from baseline in through sitting diastolic blood pressure after 8 weeks of treatment
Mean changes in sitting systolic blood pressure; response rate (defined as the proportion of patients whose sDBP was ≤90mmHg or whose sDBP had decreased from baseline by ≥10 mmHg); changes in triglyceride and total cholesterol level of blood sample
This study is completed, as verified in Sep 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
SK Chemicals Co., Ltd.